NC
MRVI icon

Nekton Capital’s Maravai LifeSciences MRVI Stock Holding History

Nekton Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-896,469
Closed -$25.5M – 22
2022
Q2 		$25.5M Sell
896,469
-214,633
-19% -$6.8M 8.21% 4
2022
Q1 		$39.2M Buy
+1,111,102
New +$37.2M 9.66% 5

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Nekton Capital's MRVI Position: Q3 2022 in Review

Nekton Capital sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 896,469 shares — an estimated $25.5M sold.

Nekton Capital first reported a position in MRVI in Q1 2022 and held it in 2 quarters. The position peaked at $39.2M in Q1 2022. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

  • Nekton Capital reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
  • Nekton Capital sold 896,469 Maravai LifeSciences shares in Q3 2022, an estimated $25.5M.
  • Nekton Capital first reported a position in Maravai LifeSciences in Q1 2022 and held it in 2 quarters.
  • Nekton Capital's Maravai LifeSciences position peaked at $39.2M in Q1 2022.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on Nekton Capital's 13F filing for Q3 2022, filed 14 Nov 2022.